{"title":"Farmaci per Smettere di Fumare","description":"\u003cp\u003eTerapia sostitutiva della nicotina per chi vuole smettere di fumare: cerotti transdermici a rilascio prolungato per il bisogno di fondo e spray per bocca ad azione rapida per la voglia improvvisa. Prodotti da banco, senza ricetta. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"nicorettequick-1mg-erogazione-spray-150-dosi","title":"NicoretteQuick 1mg\/spray 150 doses","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNicorettequick is used to treat tobacco dependence in adults by relieving nicotine withdrawal symptoms, including the desire to smoke during an attempt to quit smoking, or to reduce smoking habits before finally quitting smoking. The ultimate goal is permanent cessation of tobacco use. The use of Nicorettequick should preferably be combined with a behavioral support program.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne spray delivers 1 mg of nicotine in 0.07 ml of solution. 1 ml of solution contains 13.6 mg of nicotine. \u003cu\u003eExcipients with known effect\u003c\/u\u003e: Ethanol 7.1 mg\/dose; Propylene glycol 11 mg\/dispensing; Butylated hydroxytoluene 363 ng\/shot. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePropylene glycol (E1520), Anhydrous ethanol, Trometamol, Poloxamer 407, Glycerol (E422), Sodium hydrogen carbonate, Levomenthol, Mint flavour, Refreshing flavour, Sucralose, Acesulfame potassium, Butylated hydroxytoluene (E321), Hydrochloric acid (for pH adjustment), Purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to nicotine or to any of the excipients listed in section 6.1. • Children under 18 years old. • Subjects who have never smoked.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Support and behavioral therapy usually increase the success rate. \u003ci\u003eAdults and elderly\u003c\/i\u003e You can use up to 4 pumps per hour. Do not exceed 2 puffs for each dosage and 64 puffs (4 puffs per hour over a 16-hour period) in any 24-hour period. \u003ci\u003eAbrupt cessation of smoking\u003c\/i\u003e For smokers who want and are ready to quit smoking immediately. Individuals must stop smoking completely while taking Nicorettequick. The following graph illustrates the recommended timing of use for the oromucosal spray during the complete treatment (phase I) and during the reduction phases (phase II and phase III). \u003cb\u003ePhase I: weeks 1 to 6\u003c\/b\u003e Use 1 or 2 puffs when you would have smoked a cigarette or if you feel the desire to smoke. If a single puff does not control the urge to smoke within a few minutes, dispense a second puff. If 2 dispensings are required, it will be possible to dispense 2 consecutive dispensings in the future. Most smokers will need 1 or 2 puffs every 30 minutes to 1 hour. \u003cb\u003ePhase II: weeks 7 to 9\u003c\/b\u003e Start reducing the number of daily dispensings. By the end of week 9, subjects must have HALVED the average number of daily puffs used in phase I. \u003cb\u003ePhase III: weeks 10 to 12\u003c\/b\u003e Continue to reduce the number of puffs per day so that, in week 12, subjects are using no more than 4 puffs per day. When subjects have reduced the number of sprays to 2-4 per day, the use of the oromucosal spray should be stopped. Example: If you smoke 15 cigarettes per day on average, 1-2 puffs should be used at least 15 times throughout the day. As an aid to continuing smoking cessation after phase III, individuals may continue to use oromucosal spray in situations where they are strongly tempted to smoke. You can use a single puff in situations where you feel the urge to smoke, with a second puff if the first has had no effect within a few minutes. At this stage, no more than four sprays per day should be used. \u003ci\u003eGradual cessation through progressive reduction of smoking.\u003c\/i\u003e For smokers who do not want or are not ready for an abrupt cessation of smoking. The oromucosal spray can be used between cigarettes in order to prolong smoke-free intervals and with the aim of reducing smoking as much as possible. The patient should be aware that inappropriate use of the spray can increase adverse effects. One cigarette must be replaced with one dose (1-2 puffs) and an attempt to quit smoking must be made as soon as the smoker feels ready and in any case no later than 12 weeks from the start of treatment. If a reduction in cigarette consumption is not achieved after 6 weeks of treatment, a healthcare professional should be consulted. After smoking cessation, the number of puffs per day should be gradually reduced. When subjects have reduced administration to 2-4 sprays per day, the oromucosal spray should be discontinued. Regular use of the oromucosal spray beyond 6 months is not recommended. Some former smokers may need longer treatment with oromucosal spray to avoid starting to smoke again. Residual oromucosal spray should be saved for use in the event of a sudden desire to smoke. \u003ci\u003ePediatric population\u003c\/i\u003e Do not give Nicorettequick to anyone under 18 years of age. There is no experience in treating adolescents under 18 years of age with Nicorettequick. \u003cu\u003eMethod of administration\u003c\/u\u003e After preparation, aim the spray nozzle as close to your mouth as possible. Firmly press the top of the dispenser and release a spray into your mouth, avoiding your lips. Subjects must not inhale while dispensing, to prevent the spray from being nebulized into the respiratory tract. For best results, do not swallow for a few seconds after dispensing. Subjects should not consume food or drink at the same time as taking the oromucosal spray.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store at a temperature above 30 \u003csub\u003e°\u003c\/sub\u003eC\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNicorettequick should not be used by non-smokers. The benefits of quitting smoking outweigh any risks associated with the correct administration of nicotine replacement therapy (NRT). A risk-benefit assessment should be made by appropriate medical personnel, for patients with the following conditions: • \u003ci\u003eCardiovascular disorders: dependent smokers who have recently had a myocardial infarction, unstable or aggravated angina, including Prinzmetal's angina, serious cardiac arrhythmias or recent cerebrovascular accident and\/or those suffering from uncontrolled hypertension,\u003c\/i\u003e they must be encouraged to quit smoking through non-pharmacological interventions (e.g. counselling). If these fail, oromucosal spray may be considered but, as safety data in this patient group are limited, treatment should only be initiated under close medical supervision. • \u003ci\u003eDiabetes mellitus.\u003c\/i\u003e Patients with diabetes mellitus should be advised to monitor blood glucose levels more carefully than usual if smoking is stopped and NRT is initiated, as the reduction in nicotine-induced catecholamine release may affect carbohydrate metabolism. • \u003ci\u003eAllergic reactions\u003c\/i\u003e: predisposition to angioedema and urticaria. • \u003ci\u003eKidney damage and hepatic impairment:\u003c\/i\u003e Use with caution in patients with moderate to severe hepatic impairment and\/or severe renal impairment, as decreased clearance of nicotine or its metabolites may occur, with the possibility of increased adverse effects. • \u003ci\u003ePheochromocytoma and uncontrolled hyperthyroidism:\u003c\/i\u003e use with caution in case of uncontrolled hyperthyroidism or pheochromocytoma, as nicotine causes the release of catecholamines. • \u003ci\u003eGastrointestinal pathology:\u003c\/i\u003e nicotine can exacerbate symptoms in patients with esophagitis, gastric or peptic ulcers; NRT preparations should be used with caution under these conditions. \u003ci\u003ePediatric population\u003c\/i\u003e \u003ci\u003eDanger in children\u003c\/i\u003e: doses of nicotine tolerated by smokers can cause serious toxicity in children, even with fatal outcomes. Products containing nicotine should not be left in places where they could be handled or ingested by children; see section 4.9 Overdose. \u003ci\u003eTransmitted addiction:\u003c\/i\u003e transmitted addiction can occur, but is less harmful and easier to stop than smoking addiction. \u003ci\u003eStopping Smoking:\u003c\/i\u003e Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs metabolized by CYP1A2 (and possibly CYP1A1). When a smoker stops smoking, he or she may experience a slowdown in metabolism, resulting in increased levels of these drugs in the blood. This is potentially more clinically relevant for products with a narrow therapeutic window, such as theophylline, tacrine, clozapine and ropinirole. With cessation of tobacco use, the plasma concentration of other medicinal products metabolised in part by CYP1A2 (e.g. imipramine, olanzapine, clomipramine and fluvoxamine) may increase, although data supporting this theory are scarce and the possible clinical significance of this effect for such medicinal products is unknown. A limited amount of data indicates that smoking may induce the metabolism of flecainide and pentazocine. \u003ci\u003eExcipients:\u003c\/i\u003e This medicine contains approximately 7 mg of alcohol (ethanol) per actuation, which is equivalent to 97 mg per mL. The quantity for one shot is equivalent to less than 2 mL of beer or 1 mL of wine. The small amount of alcohol in this medicine will not have any significant effect. This medicinal product contains less than 1 mmol (23 mg) sodium per spray, i.e. it is essentially 'sodium-free'. This medicinal product contains 11 mg of propylene glycol per actuation, equivalent to 150 mg\/mL. Due to the presence of butylated hydroxytoluene, Nicorettequick may cause localized skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes. Care should be taken to avoid contact of the oromucosal spray with the eyes during administration.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo clinically significant interaction between nicotine replacement therapy and other drugs has yet been confirmed. However, nicotine may increase the haemodynamic effects of adenosine, i.e. increased blood pressure and heart rate, as well as increased painful response (angina pectoris-like chest pain) caused by adenosine administration (see section 4.4, Smoking cessation).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNicotine withdrawal effects\u003c\/i\u003e Regardless of the means used, a variety of symptoms are known to be associated with cessation of habitual tobacco use. These include emotional or cognitive effects such as dysphoria or depressed mood; insomnia; irritability, frustration, or anger; anxiety; difficulty concentrating and restlessness or impatience. Physical effects such as a decrease in heart rate may also occur; increased appetite or weight, dizziness or presyncopal symptoms, cough, constipation, bleeding gums or aphthous ulceration, or nasopharyngitis. Additionally, and of clinical importance, nicotine cravings may cause a profound urge to smoke. Nicorettequick may cause adverse reactions similar to those associated with nicotine taken in other ways and dependent primarily on dose. In susceptible individuals, allergic reactions such as angioedema, urticaria or anaphylaxis may occur. Local adverse effects of administration are similar to those observed with other forms taken orally. In the first days of treatment, mouth and throat irritation may occur; hiccups are also a particularly common effect. Habituation is normal with prolonged use. Daily data collection from study subjects demonstrated that the most common adverse events were reported with an onset in the first 2-3 weeks of oromucosal spray use, then decreasing. Adverse reactions observed with oromucosal nicotine formulations identified from clinical trials and during post-marketing experience are presented below. The frequency category was estimated from clinical studies for adverse reactions identified during post-marketing experience. Very common (≥1\/10); common (≥1\/100 to \u003c1\/10); uncommon (≥1\/1,000 to \u003c1\/100); rare (≥ 1\/10,000 to \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data).\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eCommon - Reported Adverse Reactions: Hypersensitivity\u003c\/p\u003e\n\u003cp\u003eNot known - Reported Adverse Reactions: Allergic reactions, including angioedema and anaphylaxis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eUncommon - Reported Adverse Reactions: Abnormal dreams.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eVery common - Reported Adverse Reactions: Headache.\u003c\/p\u003e\n\u003cp\u003eCommon - Reported Adverse Reactions: Dysgeusia, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eNot known - Reported Adverse Reactions: Blurred vision, increased tearing.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eUncommon - Reported Adverse Reactions: Palpitations, tachycardia.\u003c\/p\u003e\n\u003cp\u003eNot known - Reported Adverse Reactions: Atrial fibrillation.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eUncommon - Reported Adverse Reactions: Redness, hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders:\u003c\/p\u003e\n\u003cp\u003eVery common - Reported Adverse Reactions: Hiccups, throat irritation.\u003c\/p\u003e\n\u003cp\u003eCommon - Reported Adverse Reactions: Cough.\u003c\/p\u003e\n\u003cp\u003eUncommon - Reported Adverse Reactions: Bronchospasm, rhinorrhea, dysphonia, dyspnea, nasal congestion, oropharyngeal pain, sneezing, throat tightness.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery Common - Adverse Reactions Reported: Nausea.\u003c\/p\u003e\n\u003cp\u003eCommon - Reported Adverse Reactions: Abdominal pain, dry mouth, diarrhea, dyspepsia, flatulence, salivary hypersecretion, stomatitis, vomiting.\u003c\/p\u003e\n\u003cp\u003eUncommon - Reported Adverse Reactions: Belching, gingival bleeding, glossitis, blistering and exfoliation of the oral mucosa, oral paraesthesia.\u003c\/p\u003e\n\u003cp\u003eRare - Reported Adverse Reactions: Dysphagia, oral hypoesthesia, retching.\u003c\/p\u003e\n\u003cp\u003eNot known - Reported Adverse Reactions: Dry throat, gastrointestinal disorders, lip pain.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eUncommon - Reported Adverse Reactions: Hyperhidrosis, pruritus, rash, urticaria.\u003c\/p\u003e\n\u003cp\u003eNot known - Reported Adverse Reactions: Erythema.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon - Reported Adverse Reactions: Burning sensation, fatigue.\u003c\/p\u003e\n\u003cp\u003eUncommon - Reported Adverse Reactions: Asthenia, chest discomfort and pain, malaise.\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eReporting of suspected adverse reactions\u003c\/i\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at www,aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDirect symptoms of nicotine overdose may occur in patients with low pre-treatment nicotine intake or if nicotine is consumed simultaneously from multiple sources. Symptoms of overdose coincide with those of acute nicotine poisoning and include nausea, vomiting, increased salivation, abdominal pain, diarrhea, sweating, headache, dizziness, hearing disturbances and marked weakness. At high doses, these symptoms may be followed by hypotension, weak and irregular heartbeat, breathing difficulties, fatigue, circulatory collapse and generalized convulsions. \u003ci\u003ePediatric population\u003c\/i\u003e Doses of nicotine tolerated by adult smokers during treatment can cause serious symptoms of poisoning with even fatal outcomes in children. Suspected nicotine poisoning in a child should be treated as a medical emergency requiring immediate intervention. \u003ci\u003eManagement of overdose:\u003c\/i\u003e Nicotine administration should be discontinued immediately and the patient treated symptomatically. If an excessive amount of nicotine is ingested, activated charcoal reduces the gastrointestinal absorption of nicotine. The acute minimum lethal oral dose of nicotine in humans is believed to be between 40 and 60 mg.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eWomen of childbearing age \/Contraception in men and women\u003c\/i\u003e The adverse effects of tobacco smoking on human conception and pregnancy are known, while the effects of nicotine-based therapeutic treatment are unknown. Therefore, since to date no specific recommendations regarding the need for female contraception have been deemed necessary, the most prudent condition for women intending to become pregnant is not to smoke and not to use NRT. As regards men, it is known that smoking can cause adverse effects on male fertility, but there is no evidence of the need for special contraceptive measures by men during NRT treatment.\u003ci\u003ePregnancy \u003c\/i\u003e Smoking during pregnancy is associated with risks such as intrauterine growth restriction, premature birth or stillbirth. Smoking cessation is the only truly effective intervention to improve the health of the pregnant smoker and her baby. The sooner abstinence is achieved, the better the outcomes will be. Nicotine is transmitted to the fetus, with consequences on the latter's respiratory movements and circulation. The effect on circulation depends on the dose. Consequently, pregnant smokers should always be advised to completely stop smoking without resorting to nicotine replacement therapy. The risk of continued smoking may pose more serious dangers to the fetus than the use of nicotine replacement products in a controlled tobacco cessation program. The use of Nicorettequick by a pregnant smoker should only be undertaken on the advice of a healthcare professional. \u003ci\u003eBreastfeeding\u003c\/i\u003e Nicotine passes freely into breast milk in quantities sufficient to affect the baby, even at therapeutic doses. Therefore, you should avoid taking Nicorettequick while breastfeeding. If you are unable to quit smoking, the use of Nicorettequick by breast-feeding smokers should only be undertaken on the advice of a healthcare professional. Women should take the product immediately after breastfeeding and wait as long as possible (2 hours is suggested) before the next feeding. \u003ci\u003eFertility\u003c\/i\u003e Smoking increases the risk of infertility in women and men. In vitro studies have shown that nicotine can negatively affect the quality of human sperm. In rats, reduced fertility and impaired sperm quality have been demonstrated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNicorettequick has negligible or no influence on the ability to drive and use machines.\u003c\/p\u003e","brand":"Johnson \u0026 Johnson","offers":[{"title":"Default Title","offer_id":51131342291271,"sku":"042299014","price":46.48,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/johnson-johnson-spa-nicorettequick-1mg-erogazione-spray-150-dosi-farmacia-dottor-tili-1213792002.jpg?v=1767149249"},{"product_id":"cerotti-transdermici-21-mg-24-h-7-cerotti-trasparenti","title":"NiQuitin Transdermal patches 21 mg\/24 h 7 transparent patches","description":"\u003cp\u003e\n\u003cstrong\u003eTransdermal patches 21 mg\/24 h 7 transparent patches\u003c\/strong\u003e they are an effective and discreet solution for those who want \u003cstrong\u003equit smoking\u003c\/strong\u003e thanks to \u003cstrong\u003enicotine replacement therapy\u003c\/strong\u003e. Each transparent patch, designed for a \u003cstrong\u003econtinuous release of nicotine for 24 hours\u003c\/strong\u003e, helps reduce the \u003cstrong\u003ewithdrawal symptoms\u003c\/strong\u003e and the \u003cstrong\u003ecompulsive craving for nicotine\u003c\/strong\u003e, offering a valid \u003cstrong\u003esupport for quitting smoking\u003c\/strong\u003e. The package contains \u003cstrong\u003e7 transdermal patches\u003c\/strong\u003e, ideal for a week of treatment in the \u003cstrong\u003ephase 1\u003c\/strong\u003e, particularly suitable for those starting the process of quitting smoking.\n\u003c\/p\u003e\n\u003cp\u003e\nThanks to them \u003cstrong\u003etransparent formulation\u003c\/strong\u003e, the patches result \u003cstrong\u003ediscreet and easy to apply\u003c\/strong\u003e on any part of the body, ensuring comfort and convenience throughout the day. The \u003cstrong\u003edosage of 21 mg\/24 h\u003c\/strong\u003e is designed to offer a \u003cstrong\u003eEffective treatment of nicotine withdrawal\u003c\/strong\u003e in smokers who wish to gradually reduce their addiction. I \u003cstrong\u003eskin patches\u003c\/strong\u003e they are particularly suitable as \u003cstrong\u003ehelp to quit smoking\u003c\/strong\u003e and represent one of the most used and recommended solutions in online pharmacies for \u003cstrong\u003etreatment of nicotine withdrawal\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nChoose i \u003cstrong\u003etransdermal patches 21 mg\/24 h\u003c\/strong\u003e it means relying on one \u003cstrong\u003econtrolled release technology\u003c\/strong\u003e which allows you to effectively manage withdrawal symptoms, promoting success in the smoking cessation process. Ideal for those looking \u003cstrong\u003epatches for smokers\u003c\/strong\u003e who want a \u003cstrong\u003econcrete and scientifically validated help\u003c\/strong\u003e to abandon nicotine addiction.\n\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Transdermal Patches 21 mg\/24 h 7 transparent patches used? What is it for?\u003c\/h3\u003e\u003cp\u003eTransdermal patch releasing nicotine 21 mg\/24h, indicated as nicotine replacement therapy to support smoking cessation; helps reduce withdrawal symptoms and compulsive cravings for nicotine.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Transdermal patches 21 mg\/24 h 7 transparent patches?\u003c\/h3\u003e\u003cp\u003e7 transparent plasters\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Perrigo","offers":[{"title":"Default Title","offer_id":51730205606215,"sku":"034283869","price":43.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/perrigo-italia-srl-cerotti-transdermici-21-mg-24-h-7-cerotti-trasparenti-farmacia-dottor-tili-1213791375.jpg?v=1767139570"}],"url":"https:\/\/www.dottortili.com\/en\/collections\/farmaci-per-smettere-di-fumare.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}